XML 47 R30.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of fair value of Level 3 derivative liabilities (except the Public Special Purpose Acquisition Companies (“SPAC”) warrants as defined below, which are Level 1 derivative liabilities that are measured at fair value on a recurring basis

		For the Year Ended December 31, 2021
		Warrants
		Public				Private												Convertible
		SPAC				SPAC				PIPE				Other				Notes				Total
Balance as of January 1, 2021		$	3,795,000			$	256,275			$	-			$	165,895			$	225,800			$	4,442,970
Extinguishment of derivative liabilities in connection with conversion of debt ⁽¹⁾			-				-				-				-				(591,203	)			(591,203	)
Warrants issued in connection with the financing			-				-				7,294,836				-				-				7,294,836
Warrants issued relates to Alpha settlement ⁽¹⁾			-				-				-				95,677				-				95,677
Extinguishment of derivative liabilities in connection with the Alpha settlement ⁽¹⁾			-				-				-				-				(699,301	)			(699,301	)
Change in fair value of derivative liabilities			4,253,850				211,050				(778,536	)			(73,680	)			1,064,704				4,677,388
Balance as of December 31, 2021		$	8,048,850			$	467,325			$	6,516,300			$	187,892			$	-			$	15,220,367

Schedule of derivative liabilities

		For the Year Ended December 31, 2020
		Warrants				Convertible Notes				Preferred Stock				Total
Beginning balance as of January 1, 2020		$	-			$	-			$	-			$	-
Derivative liabilities assumed at date of Business Combination			2,754,865			$	23,500			$	1,167,000			$	3,945,365
Derecognition of derivative liabilities in connection with convertible note and preferred stock modification and exchanges			-				(723,336	)			(2,033,068	)			(2,756,404	)
Issuance of derivative liabilities			-				1,219,700				218,000				1,437,700
Change in fair value of derivative liabilities			1,462,305				(294,064	)			648,068				1,816,309
Ending balance as of December 31, 2020		$	4,217,170			$	225,800			$	-			$	4,442,970

Schedule of option pricing models to derivatives assumed

		December 31, 2021
Risk-free interest rate			0.85% - 1.14	%
Expected term in years			2.59 - 4.15
Expected volatility			98.5	%
Expected dividends			0	%

		November 6,
		2020
Risk-free interest rate			0.08% - 0.40	%
Expected term (years)			0.26 - 5.01
Expected volatility			80% - 207	%
Expected dividends			0.00	%

		November 25, 2020
Risk-free interest rate			0.06% - 0.09	%
Expected term (years)			0.24 - 0.54
Expected volatility			115% - 160	%
Expected dividends			0.00	%

February 23,
2021

Risk-free interest rate 0.59 %

Expected term in years 5.00

Expected volatility 85 %

Expected dividends 0 %

		March 12, 2021
Risk-free interest rate			0.68	%
Expected term in years			3.84
Expected volatility			85	%
Expected dividends			0	%

		July 29, 2021
Risk-free interest rate			0.37	%
Expected term in years			3.00
Expected volatility			85	%
Expected dividends			0	%

		January 15, 2021 to
		February 5, 2021
Risk-free interest rate			0.00% - 0.14	%
Expected term in years			0.02 - 0.18
Expected volatility			120% - 161	%
Expected dividends			0	%

Schedule of warrant activity

		Number of Warrants				Weighted Average Exercise Price				Weighted Average Remaining Life in Years			Intrinsic Value
Outstanding, January 1, 2020			-				-
Issued			6,064,908				11.43
Outstanding, December 31, 2020			6,064,908				11.43
Issued			5,089,000				6.24
Exercised			-				-
Cancelled			-				-
Expired			-				-
Outstanding, December 31, 2021			11,153,908			$	9.06				4.1

Exercisable, December 31, 2021			11,153,908			$	9.06				4.1

Schedule of outstanding and exercisable warrants

Warrants Outstanding								Warrants Exercisable
								Weighted
								Average
Exercise				Number of				Remaining				Number of
Price				Shares				Life in Years				Shares
$	5.00				2,564,000				4.2				2,564,000
$	5.28				63,658				3.3				63,658
$	7.07				25,000				2.6				25,000
$	7.50				2,500,000				4.6				2,500,000
$	11.50				6,001,250				3.9				6,001,250
					11,153,908				4.1				11,153,908

Warrants Outstanding								Warrants Exercisable
								Weighted
								Average
Exercise				Number of				Remaining				Number of
Price				Shares				Life in Years				Shares
$	11.50				6,001,250				4.9				6,001,250
	5.28				63,658								-
					6,064,908				4.9				6,001,250

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details